Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Mature
Primary summary from verified readiness
- Confidence
- 66% · fresh
- Computed at
- 2026-08-20T10:56:11.504085+00:00
- Claimed
- 88
- Reported
- 84
- Verified
- 75
- Gap
- +13
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Adopt with guardrails
- Why
- FDA-approved with peer-reviewed Phase 3 superiority data over standard-dose vaccines in adults 50+ (NEJM, May 2026) and platform-level EU precedent (Mcombriax), but the accelerated-approval carve-out for the 65+ subgroup -- the population carrying 70-85% of flu mortality -- is a real, disclosed regulatory guardrail, not yet closed.
- Next
- Track the confirmatory-trial outcome for the 65+ accelerated-approval indication and the EU/Canada/Australia regulatory decisions before treating mFlusiva as fully de-risked across its full label.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 5
- Tier 1
- 1
- Tier 2
- 1
- Tier 3
- 3
- Supports
- 3
- Contradicts
- 1
- Context
- 1
- Latest observed
- 2026-08-06
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-08-17 Reading moved from mature to mature.